1. Council Recommendation of 8 June 2009 on an action in the field of rare diseases. Official Journal of the European Union 2009/C 151/02 of 8 June 2009.
https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF
.
2. Inventory of Union and Member State incentives to support research into, and the development and availability of, orphan medicinal products - Final state of Play 2015.
https://ec.europa.eu/health//sites/health/files/files/orphanmp/doc/orphan_inv_report_20160126.pdf
. Accessed 26 Mar 2019.
3. The committee for orphan medicinal products and the European medicines agency scientific secretariat. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov. 2011;10:341–9.
4. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Weesgeneesmiddelen: een Belgische en Europese analyse. Farmaceutisch tijdschrift Voor België. 2009;4:109–15.
5. Communication from the commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the regions, on rare diseases: Europe’s challenges.
https://publications.europa.eu/en/publication-detail/-/publication/c8a042d8-ffb9-4b01-9c91-c1497a2b3fd7/language-en
. Accessed 26 Mar 2019.